Some use LNPs to deliver mRNAs that can downregulate the expression of oncogenes, such as the MYC transcription factor, or upregulate the expression of tumor suppressor genes, such as the gene encoding alpha CCAAT enhancer-binding protein (CEBPA, also known as C/EBPα). This evidence concerns the gene CEBPA and neoplasm.